AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17094983 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily GnRH agonist (buserelin) administration
Number of subjects: 2
Study 17094983 — intervention group
Group type: COMPARATOR
Intervention: Recombinant FSH
Number of subjects: 2
Study 17094983 — intervention group
Group type: COMPARATOR
Intervention: hMG
Number of subjects: 2
Study 15656468 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrogel dressing
Number of subjects: 27
Study 15656468 — intervention group
Group type: COMPARATOR
Intervention: Conservative topical wound-care regimen (gauze with povidone-iodine)
Number of subjects: 27
Study 11879861 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid injections
Number of subjects: 185
Study 11879861 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Number of subjects: 185
Study 11879861 — intervention group
Group type: EXPERIMENTAL
Intervention: Wait-and-see policy
Number of subjects: 185
Study 9527747 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose opioid anaesthesia (thoracic epidural analgesia combined with inhalational anaesthesia)
Number of subjects: 16
Study 9527747 — intervention group
Group type: COMPARATOR
Intervention: High-dose fentanyl anaesthesia
Number of subjects: 16
Study 9527747 — intervention group
Group type: EXPERIMENTAL
Intervention: Both anaesthesia types
Number of subjects: 16
Study 8527269 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-0591 (50, 125, 250, 500 mg single doses)
Number of subjects: 50
Study 8527269 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-0591 (125 mg twice daily for 9.5 days)
Number of subjects: 50
Study 8527269 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-0591 (250 mg single dose)
Number of subjects: 50
Study 8527269 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-0591 (single dose)
Number of subjects: 50
Study 2404455 — intervention group
Group type: EXPERIMENTAL
Intervention: Immuno-chemotherapy combined with PSK 3 g/day
Number of subjects: 169
Study 2404455 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (CDDP 100 mg/m2 day 1, VDS 3 mg/m2 day 1, 8, 15)
Number of subjects: 169
Study 359024 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfametopyrazine given once a week over one winter
Number of subjects: 218
Study 359024 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 218
Study 30691519 — intervention group
Group type: EXPERIMENTAL
Intervention: Levothyroxine (LT4) treatment
Number of subjects: 0
Study 30691519 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 0
Study 28659234 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginger (250 mg ginger capsules from the onset of menstruation)
Number of subjects: 122
Study 28659234 — intervention group
Group type: COMPARATOR
Intervention: Stretching exercises (belly and pelvic stretching exercises for 10 min, 3 times per week)
Number of subjects: 122
Study 28659234 — intervention group
Group type: COMPARATOR
Intervention: Stretching exercises
Number of subjects: 122
Study 25835438 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Statin Therapy (HIST)
Number of subjects: 3495
Study 25835438 — intervention group
Group type: COMPARATOR
Intervention: Low-Intensity Statin Therapy (LIST)
Number of subjects: 3495
Study 25835438 — intervention group
Group type: COMPARATOR
Intervention: No-Statin Therapy
Number of subjects: 3495
Study 25629243 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition on the Go strategy
Number of subjects: 0
Study 25629243 — intervention group
Group type: COMPARATOR
Intervention: PG 3 (low availability of food and medium SEI)
Number of subjects: 0
Study 21039931 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic additive B (Bacillus cereus var. toyoi, 1.6 × 10(6) spores per gram of feed)
Number of subjects: 120
Study 21039931 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic additive A (Bacillus subtilis and Bacillus licheniformis, 1.6 × 10(6) spores per gram of feed)
Number of subjects: 120
Study 21039931 — intervention group
Group type: COMPARATOR
Intervention: Control (regular corn-soy meal based feed)
Number of subjects: 120
Study 21039931 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic additive A
Number of subjects: 120
Study 21039931 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic additive B
Number of subjects: 120
Study 19423109 — intervention group
Group type: EXPERIMENTAL
Intervention: Corn oil enriched diet
Number of subjects: 30
Study 17969367 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan (angiotensin II receptor blocker)
Number of subjects: 0
Study 17969367 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15138463 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 g/day alcohol
Number of subjects: 53
Study 15138463 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 g/day alcohol
Number of subjects: 53
Study 15138463 — intervention group
Group type: COMPARATOR
Intervention: 0 g/day alcohol (control)
Number of subjects: 53
Study 12578244 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm exercises
Number of subjects: 20
Study 12578244 — intervention group
Group type: EXPERIMENTAL
Intervention: Leg exercises
Number of subjects: 20
Study 12578244 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm and leg exercises
Number of subjects: 20
Study 11477813 — intervention group
Group type: EXPERIMENTAL
Intervention: Purified Xuefu Capsule (PXFC) and western medicine
Number of subjects: 57
Study 11477813 — intervention group
Group type: COMPARATOR
Intervention: Western medicine (isosorbide dinitrate, diltiazem or atenolol)
Number of subjects: 57
Study 11477813 — intervention group
Group type: EXPERIMENTAL
Intervention: Purified Xuefu Capsule (PXFC)
Number of subjects: 57
Study 7865804 — intervention group
Group type: EXPERIMENTAL
Intervention: Calculated energy requirements using the Harris Benedict Equation (HBE)
Number of subjects: 20
Study 7865804 — intervention group
Group type: EXPERIMENTAL
Intervention: Indirect calorimetry measurements
Number of subjects: 20
Study 2744969 — intervention group
Group type: EXPERIMENTAL
Intervention: Task condition with cutaneous stimulation on the right hand
Number of subjects: 0
Study 2744969 — intervention group
Group type: EXPERIMENTAL
Intervention: Task condition with cutaneous stimulation on the left hand
Number of subjects: 0
Study 2744969 — intervention group
Group type: COMPARATOR
Intervention: Control condition (attending to electrical pulses)
Number of subjects: 0
Study 667231 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol (0.5 mg injection)
Number of subjects: 12
Study 667231 — intervention group
Group type: EXPERIMENTAL
Intervention: Apomorphine
Number of subjects: 12
Study 667231 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 12
Study 29101631 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed cord clamping (DCC) for 60 seconds or cord milking (CM)
Number of subjects: 215
Study 29101631 — intervention group
Group type: COMPARATOR
Intervention: Early cord clamping (ECC) within 10 seconds
Number of subjects: 215
Study 27678433 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral-fat tolerance test (OFTT)
Number of subjects: 2117
Study 27678433 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral-fat tolerance test (OFTT) in CORDIOPREV study
Number of subjects: 2117
Study 27678433 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral-fat tolerance test (OFTT) in GOLDN study
Number of subjects: 2117
Study 23877305 — intervention group
Group type: EXPERIMENTAL
Intervention: Single shot femoral nerve block (FNB) using 15mL bupivacaine 0.25% and 20 mg clonidine
Number of subjects: 80
Study 23877305 — intervention group
Group type: EXPERIMENTAL
Intervention: Single shot femoral nerve block (FNB)
Number of subjects: 80
Study 23877305 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment without nerve block (STN)
Number of subjects: 80
Study 22736302 — intervention group
Group type: EXPERIMENTAL
Intervention: Etravirine (NNRTIs)
Number of subjects: 0
Study 22736302 — intervention group
Group type: EXPERIMENTAL
Intervention: Maraviroc (CRAs)
Number of subjects: 0
Study 22736302 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK1349572 (INSTIs)
Number of subjects: 0
Study 22736302 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir (NtRTIs)
Number of subjects: 0
Study 20552926 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin (up to 900 mg/d)
Number of subjects: 0
Study 20552926 — intervention group
Group type: COMPARATOR
Intervention: Placebo or lowest dose of gabapentin (300 mg/d)
Number of subjects: 0
Study 18514114 — intervention group
Group type: EXPERIMENTAL
Intervention: Absorbable sutures
Number of subjects: 50
Study 18514114 — intervention group
Group type: COMPARATOR
Intervention: Nonabsorbable sutures
Number of subjects: 50
Study 16075063 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy
Number of subjects: 0
Study 12461037 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin administered alone
Number of subjects: 12
Study 12461037 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone administered alone
Number of subjects: 12
Study 12461037 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin and ceftriaxone administered concurrently
Number of subjects: 12
Study 12461037 — intervention group
Group type: COMPARATOR
Intervention: Control arm (azithromycin and ceftriaxone administered alone)
Number of subjects: 12
Study 10656205 — intervention group
Group type: COMPARATOR
Intervention: Calcium (500 mg b.i.d.) and 1000 IU vitamin D3
Number of subjects: 33
Study 10656205 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium (500 mg b.i.d.) and 1000 IU vitamin D3 with retarded-release sodium fluoride (25 mg t.i.d.)
Number of subjects: 33
Study 8641119 — intervention group
Group type: EXPERIMENTAL
Intervention: Leucocyte lysates from patients with microalbuminuria
Number of subjects: 57
Study 8641119 — intervention group
Group type: EXPERIMENTAL
Intervention: Leucocyte lysates from patients with proteinuria
Number of subjects: 57
Study 8641119 — intervention group
Group type: COMPARATOR
Intervention: Leucocyte lysates from control subjects with normal AER
Number of subjects: 57
Study 8641119 — intervention group
Group type: COMPARATOR
Intervention: Leucocyte lysates from NIDDM subjects with normal AER
Number of subjects: 57
Study 1888048 — intervention group
Group type: COMPARATOR
Intervention: Epidural fentanyl (100 micrograms in 10 ml isotonic saline)
Number of subjects: 20
Study 1888048 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural fentanyl (100 micrograms in 10 ml isotonic saline) plus epidural clonidine (150 micrograms)
Number of subjects: 20
Study 6685597 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette smoking
Number of subjects: 0
Study 6685597 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin + Cigarette smoking
Number of subjects: 0
Study 6685597 — intervention group
Group type: COMPARATOR
Intervention: Oral nicotine
Number of subjects: 0
Study 6685597 — intervention group
Group type: COMPARATOR
Intervention: Herbal (nicotine-free) cigarettes
Number of subjects: 0
Study 6685597 — intervention group
Group type: COMPARATOR
Intervention: Nicotine chewing gum
Number of subjects: 0
Study 31829266 — intervention group
Group type: EXPERIMENTAL
Intervention: Pragmatic approach to randomised trials
Number of subjects: 17
Study 31829266 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexibility in intervention delivery
Number of subjects: 17
Study 31829266 — intervention group
Group type: EXPERIMENTAL
Intervention: Levels of resourcing and adherence steps
Number of subjects: 17
Study 31829266 — intervention group
Group type: EXPERIMENTAL
Intervention: Pragmatic approach to population and trial setting
Number of subjects: 17
Study 29066122 — intervention group
Group type: EXPERIMENTAL
Intervention: RT + HT (30 Gy in 10 fractions combined with hyperthermia, performed by Thermotron RF‐8, target temperature maintained for 40 minutes, twice weekly for 2 weeks)
Number of subjects: 57
Study 29066122 — intervention group
Group type: EXPERIMENTAL
Intervention: RT + HT
Number of subjects: 57
Study 29066122 — intervention group
Group type: COMPARATOR
Intervention: RT alone
Number of subjects: 57
Study 26935286 — intervention group
Group type: EXPERIMENTAL
Intervention: Spacelabs 90217A
Number of subjects: 40
Study 26935286 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobil-O-Graph NG
Number of subjects: 40
Study 26935286 — intervention group
Group type: COMPARATOR
Intervention: Mercury sphygmomanometer
Number of subjects: 40
Study 26645514 — intervention group
Group type: EXPERIMENTAL
Intervention: Davaie Loban (DL)
Number of subjects: 44
Study 26645514 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 22651239 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple-site CRT
Number of subjects: 100
Study 22651239 — intervention group
Group type: COMPARATOR
Intervention: Conventional CRT
Number of subjects: 100
Study 20448860 — intervention group
Group type: EXPERIMENTAL
Intervention: Iontophoresis of 1% Acetylcholine (ACh) with laser Doppler fluximetry (LDF)
Number of subjects: 0
Study 20448860 — intervention group
Group type: EXPERIMENTAL
Intervention: Iontophoresis of 1% Sodium Nitroprusside (SNP) with laser Doppler fluximetry (LDF)
Number of subjects: 0
Study 18243724 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide at 4 mg/h
Number of subjects: 42
Study 18243724 — intervention group
Group type: COMPARATOR
Intervention: Saline at 2 ml/h (Control)
Number of subjects: 42
Study 18243724 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide
Number of subjects: 42
Study 18243724 — intervention group
Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 42
Study 16162041 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced web site
Number of subjects: 5785
Study 16162041 — intervention group
Group type: COMPARATOR
Intervention: Basic web site
Number of subjects: 5785
Study 16162041 — intervention group
Group type: EXPERIMENTAL
Intervention: Mailings to principals and directors
Number of subjects: 5785
Study 11971667 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose (n = 8)
Number of subjects: 37
Study 11971667 — intervention group
Group type: COMPARATOR
Intervention: Protein (n = 10)
Number of subjects: 37
Study 11971667 — intervention group
Group type: COMPARATOR
Intervention: Fat (n = 10)
Number of subjects: 37
Study 11971667 — intervention group
Group type: COMPARATOR
Intervention: Water (n = 9)
Number of subjects: 37
Study 10188139 — intervention group
Group type: COMPARATOR
Intervention: nCPAP
Number of subjects: 50
Study 10188139 — intervention group
Group type: COMPARATOR
Intervention: Surgical treatment (uvulopalatopharyngoplasty with or without mandibular osteotomy)
Number of subjects: 50
Study 7751690 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternating zidovudine and didanosine therapy
Number of subjects: 26
Study 7751690 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous zidovudine and didanosine therapy
Number of subjects: 26
Study 2260198 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorghum-based oral rehydration solution (ORS)
Number of subjects: 64
Study 2260198 — intervention group
Group type: COMPARATOR
Intervention: WHO recommended ORS
Number of subjects: 64
Study 2260198 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorghum-based ORS
Number of subjects: 64
Study 2260198 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 64
Study 6805243 — intervention group
Group type: EXPERIMENTAL
Intervention: 20/250 combination of ethinylestradiol and levonorgestrel
Number of subjects: 98
Study 6805243 — intervention group
Group type: EXPERIMENTAL
Intervention: 30/250 combination of ethinylestradiol and levonorgestrel
Number of subjects: 98
Study 6805243 — intervention group
Group type: EXPERIMENTAL
Intervention: 30/150 combination of ethinylestradiol and levonorgestrel
Number of subjects: 98
Study 6805243 — intervention group
Group type: EXPERIMENTAL
Intervention: Triphasic drug combination of ethinylestradiol and levonorgestrel
Number of subjects: 98
Study 31279326 — intervention group
Group type: EXPERIMENTAL
Intervention: TVS inserted percutaneously with fluoroscopy
Number of subjects: 96
Study 31279326 — intervention group
Group type: COMPARATOR
Intervention: TVS inserted percutaneously without fluoroscopy
Number of subjects: 96
Study 30650499 — intervention group
Group type: EXPERIMENTAL
Intervention: Compound Xuanju Capsule (CXC)
Number of subjects: 300
Study 30650499 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 300
Study 25751829 — intervention group
Group type: EXPERIMENTAL
Intervention: Femtosecond laser-assisted cataract surgery without OVD
Number of subjects: 37
Study 25751829 — intervention group
Group type: COMPARATOR
Intervention: Standard phacoemulsification with OVD
Number of subjects: 37
Study 23880826 — intervention group
Group type: EXPERIMENTAL
Intervention: Conformal radiotherapy (CFRT) with 64 Gy and a 1.0- or 1.5-cm margin
Number of subjects: 126
Study 23880826 — intervention group
Group type: EXPERIMENTAL
Intervention: Conformal radiotherapy (CFRT) with a ±10 Gy boost to the prostate alone
Number of subjects: 126
Study 23880826 — intervention group
Group type: EXPERIMENTAL
Intervention: Conformal radiotherapy (CFRT)
Number of subjects: 126
Study 23880826 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose escalation
Number of subjects: 126
Study 21844495 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin plus pegylated liposomal doxorubicin (PLD) 30 mg/m²
Number of subjects: 820
Study 21844495 — intervention group
Group type: COMPARATOR
Intervention: Carboplatin plus paclitaxel 175 mg/m²
Number of subjects: 820
Study 19659999 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone (4 mg day(-1) for 12 weeks)
Number of subjects: 199
Study 20880431 — intervention group
Group type: EXPERIMENTAL
Intervention: Capnometry
Number of subjects: 63
Study 20880431 — intervention group
Group type: COMPARATOR
Intervention: Pulse Oximetry
Number of subjects: 63
Study 16274596 — intervention group
Group type: EXPERIMENTAL
Intervention: rFSH + HMG
Number of subjects: 94
Study 16274596 — intervention group
Group type: EXPERIMENTAL
Intervention: rFSH + rLH
Number of subjects: 94
Study 12145173 — intervention group
Group type: EXPERIMENTAL
Intervention: L-NMMA (6 mg/kg total dose)
Number of subjects: 18
Study 12145173 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 9927359 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampin-monoresistant tuberculosis (RMR-TB) patients
Number of subjects: 69
Study 9927359 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampin-monoresistant tuberculosis (RMR-TB) patients with a history of TB
Number of subjects: 69
Study 7473124 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin surface modified (HSM) IOL
Number of subjects: 54
Study 7473124 — intervention group
Group type: COMPARATOR
Intervention: Poly(methyl methacrylate) (PMMA) IOL
Number of subjects: 54
Study 2176815 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 ml 1.4% mepivacaine with epinephrine (1:200,000) and 4 mEq of NaHCO3
Number of subjects: 40
Study 2176815 — intervention group
Group type: COMPARATOR
Intervention: 40 ml 1.4% mepivacaine with epinephrine (1:200,000)
Number of subjects: 40
Study 7467378 — intervention group
Group type: EXPERIMENTAL
Intervention: K. H. 3 (medication)
Number of subjects: 200
Study 7467378 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 30507225 — intervention group
Group type: EXPERIMENTAL
Intervention: Associative No‐Go ICT
Number of subjects: 246
Study 30507225 — intervention group
Group type: EXPERIMENTAL
Intervention: Associative Stop Signal ICT
Number of subjects: 246
Study 30507225 — intervention group
Group type: EXPERIMENTAL
Intervention: General Inhibition ICT
Number of subjects: 246
Study 30507225 — intervention group
Group type: COMPARATOR
Intervention: Active control
Number of subjects: 246
Study 27083066 — intervention group
Group type: EXPERIMENTAL
Intervention: SCMMF dissection in 30 (23.1%) patients
Number of subjects: 130
Study 27083066 — intervention group
Group type: COMPARATOR
Intervention: Non-SCMMF group
Number of subjects: 130
Study 27083066 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up examinations at 6, 12, and 24 months
Number of subjects: 130
Study 27083066 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall patient feedback after 2 years
Number of subjects: 130
Study 24929796 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoprostenol at 1 ng/kg/min
Number of subjects: 90
Study 24929796 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoprostenol at 2 ng/kg/min
Number of subjects: 90
Study 24929796 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 22122289 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Weight group-based 4-hr prevention program
Number of subjects: 398
Study 22122289 — intervention group
Group type: COMPARATOR
Intervention: Educational brochure control condition
Number of subjects: 398
Study 20150289 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifrequency bioelectrical impedance (BI) method for estimating visceral fat area (VFA)
Number of subjects: 103
Study 18762589 — intervention group
Group type: EXPERIMENTAL
Intervention: Paternal age 55 years and older
Number of subjects: 13428
Study 18762589 — intervention group
Group type: EXPERIMENTAL
Intervention: Paternal age <20 years (early-onset cases)
Number of subjects: 13428
Study 18762589 — intervention group
Group type: COMPARATOR
Intervention: Paternal age 20 to 24 years (reference group)
Number of subjects: 13428
Study 16391447 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus acidophilus
Number of subjects: 98
Study 16391447 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study 12450887 — intervention group
Group type: EXPERIMENTAL
Intervention: Diacylglycerol oil
Number of subjects: 131
Study 12450887 — intervention group
Group type: COMPARATOR
Intervention: Triacylglycerol oil
Number of subjects: 131
Study 10624640 — intervention group
Group type: COMPARATOR
Intervention: 1 mg/kg lidocaine 2% mixed with 0.5 mg/kg bupivacaine 0.5% without epinephrine (pH = 6.3)
Number of subjects: 144
Study 10624640 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg/kg lidocaine 2% mixed with 0.5 mg/kg bupivacaine 0.5% with 8.4% sodium bicarbonate (mean final pH = 6.90)
Number of subjects: 144
Study 10624640 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg/kg lidocaine 2% mixed with 0.5 mg/kg bupivacaine 0.5% with 8.4% sodium bicarbonate (mean final pH = 7.16)
Number of subjects: 144
Study 10624640 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg/kg lidocaine 2% mixed with 0.5 mg/kg bupivacaine 0.5% with 8.4% sodium bicarbonate (mean final pH = 7.43)
Number of subjects: 144
Study 8835616 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (80 micrograms/kg/s.c.)
Number of subjects: 34